Rebuttal to Deacon and Holst: "Metformin effects on dipeptidyl peptidase IV degradation of glucagon-like peptide-1" versus "Dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective".
Demuth
Hans-Ulrich
HU
Probiodrug AG, Biocenter, Weinbergweg 22, D-06120 (Saale), Halle, Germany.
Hinke
Simon A
SA
Pederson
Raymond A
RA
McIntosh
Christopher H S
CH
D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism* / Q000517:prevention & control; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism*; D005749:Gastric Inhibitory Polypeptide / Q000378:metabolism; D005934:Glucagon / Q000378:metabolism*; D052216:Glucagon-Like Peptide 1; D006801:Humans; D007004:Hypoglycemic Agents / Q000378:metabolism / Q000494:pharmacology*; D008687:Metformin / Q000378:metabolism / Q000494:pharmacology*; D010446:Peptide Fragments / Q000378:metabolism*; D011480:Protease Inhibitors / Q000378:metabolism / Q000494:pharmacology; D011498:Protein Precursors / Q000378:metabolism*
D007004:Hypoglycemic Agents; D010446:Peptide Fragments; D011480:Protease Inhibitors; D011498:Protein Precursors; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D008687:Metformin; D018819:Dipeptidyl Peptidase 4